Kite Pharma
KITE

from December 31, 2015 to December 31, 2016 Issuances under equity incentive plans Employee stock purchase plan

from December 31, 2014 to December 31, 2015 Stock option exercise Issuance of common stock, net Issuance of common stock related to acquisition Common stock warrants exercised Employee stock purchase plan

from January 1, 2015 to September 30, 2015 Stock option exercises Issuance of common stock, net Issuance of common stock related to acquisition Common stock warrants exercised Employee stock purchase plan

from January 1, 2015 to June 30, 2015 Stock option exercise Issuance of common stock, net Issuance of common stock related to acquisition Common stock warrants exercised Employee stock purchase plan

from January 1, 2015 to March 31, 2015 Stock option exercise Issuance of common stock, net Issuance of common stock related to acquisition Common stock warrants exercised Employee stock purchase plan shares issued

from December 31, 2013 to December 31, 2014 Conversion of preferred stock into common stock Stock based compensation for services Stock option exercise Issuance of common stock, net Conversion of convertible notes into common stock Payment of preferred stock dividend in common stock

from January 1, 2014 to September 30, 2014 Conversion of preferred stock into common stock Stock option exercise Issuance of common stock in initial public offering, net Conversion of convertible notes into common stock Payment of preferred stock dividend in common stock

from January 1, 2014 to June 30, 2014 Conversion of preferred stock into common stock Stock option exercise Issuance of common stock in initial public offering, net Conversion of convertible notes into common stock Payment of preferred stock dividend in common stock

The conversion of all our outstanding Series A convertible preferred stock, plus accrued dividends, into an aggregate of 20,463,899 shares of common stock in connection with the closing of this offering, based on the initial public offering price of $17.00 per share and a conversion date of June 25, 2014; The conversion of all outstanding warrants exercisable for 159,049 shares of Series A convertible preferred stock into warrants exercisable for 159,049 shares of common stock upon completion of this offering; The issuance of 3,300,735 shares of common stock in connection with the closing of this offering as a result of the automatic conversion of the $50.0 million aggregate principal amount of convertible promissory notes issued in April 2014, or the 2014 Notes, plus accrued interest thereon, based on the initial public offering price of $17.00 per share and a conversion date of June 25, 2014;

from December 31,2013 to March 31, 2014 Stock option exercise